Overcoming cancer drug resistance

Pipeline

Cancer drug resistance

INVESTORS

Interim Report Q1 2022

Rights Issue 2022

Read more

Interim Report Q1 2022

President & CEO Bo Rode Hansen reflects on our achievements and outlook for 2022

PRESS RELEASES

Subscription period in Scandion Oncology Rights Issue of up to approximately SEK 93.7 million commences

The Rights Issue is also open for subscriptions to the public.

Scandion Oncology publishes prospectus in connection with the rights issue of up to approximately SEK 93.7 million

The prospectus has today been approved and registered by the Danish Financial Supervisory Authority (Finanstilsynet).

Invitation to Scandion Oncology webcast and conference call June 10, 2022

Scandion Oncology’s Executive Management will host a webcast and conference call presenting the upcoming Rights Issue

View all press releases

UPCOMING EVENTS

BACR

Meet Scandion Oncology at the BACR 60th Anniversary Meeting

Interim report Q2 2022

LSX Nordic Congress

Meet Scandion Oncology at LSX Nordic 2022

View all upcoming events

Learn more about our unique first-in-class lead compound SCO-101

Read more about SCO-101

LATEST PRESENTATIONS

Redeye Transactions

Watch President & CEO Bo Rode Hansen’s presentation from Redeye Transactions

Aktiespararna

Watch Chief Operating Officer Maj Hedtjärn present Scandion at Aktiespararna Småbolagsdagarna 2022

DAF Interview

Watch President and CEO Bo Rode Hansen present Scandion to The Danish Shareholder Association

View all presentations

INVESTOR

Scandion Oncology Capital Markets Day

September 8, 2021

Watch the presentations from Scandion Oncology’s Capital Markets Day

Capital Markets Day View all presentations

CAREER

A great place to work

For talented, ambitious individuals who share our passion for science and drug development, we offer an exciting work environment, along with the opportunity to make a difference for the many cancer patients in need for novel treatments